11,804 Shares in Stryker Corporation $SYK Bought by North Dakota State Investment Board

North Dakota State Investment Board bought a new position in shares of Stryker Corporation (NYSE:SYK) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 11,804 shares of the medical technology company’s stock, valued at approximately $4,149,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Corient Private Wealth LLC increased its holdings in Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Stryker by 13.3% in the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after buying an additional 741,542 shares in the last quarter. Strive Asset Management LLC purchased a new position in Stryker in the third quarter valued at $227,389,000. Credit Agricole S A purchased a new position in Stryker in the third quarter valued at $194,045,000. Finally, Pictet Asset Management Holding SA increased its holdings in Stryker by 190.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company’s stock valued at $163,878,000 after buying an additional 305,640 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Barclays cut their price objective on shares of Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. BTIG Research cut their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a report on Friday, May 1st. Wells Fargo & Company cut their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Finally, Canaccord Genuity Group cut their price objective on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $395.48.

Insider Activity

In other news, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is currently owned by company insiders.

Stryker Stock Down 0.0%

Shares of NYSE SYK opened at $306.74 on Monday. The company’s 50-day simple moving average is $329.68 and its 200-day simple moving average is $351.50. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a market cap of $117.59 billion, a price-to-earnings ratio of 35.50, a price-to-earnings-growth ratio of 1.93 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business earned $2.84 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.